Please login to the form below

Not currently logged in
Email:
Password:

Roche signs exclusive distribution deal

Roche has signed an exclusive distribution deal with DxS for two cancer tests designed to help assist doctors in identifying suitable patients for treatment
Roche has signed an exclusive distribution deal with DxS for two cancer tests designed to help assist doctors in identifying suitable patients for treatment.

The K-RAS test will aid in the selection of suitable colorectal cancer patients for treatment, whereas the EGFR 29 test will aid doctors in selecting lung cancer patients suitable for treatment with some inhibitor therapies.

The European Commission recently granted a conditional marketing authorisation for a potential treatment for patients with non-mutated K-RAS genes who do not respond to standard chemotherapy regimens.

Daniel O'Day, president and CEO of Roche Molecular Diagnostics said: "There is a growing demand for tests to indicate disease prognosis and identify patient groups more likely to benefit from a particular drug."

Roche has been granted exclusive worldwide distribution rights for the K-RAS test, and exclusive distribution rights inall global markets except the US, Canada, Mexico and Hong Kong for the EGFR 29 test. Both tests have CE Mark certification in Europe.

"Not only does it [the distribution agreement] enable us to meet the growing demand for these tests, but it also gives doctors and patients access to standardised test results that provide further information to enhance treatment decisions," said Dr Stephen Little, CEO of DxS.

2nd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....

Infographics